Cargando…

Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial

OBJECTIVES: This study evaluated the safety of topical lipoic acid choline ester (UNR844, 1.5%) ophthalmic solution and its efficacy in improving distance-corrected near visual acuity (DCNVA) in subjects with presbyopia. SUBJECTS AND METHODS: This was a prospective, randomized, double-masked, and mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Korenfeld, Michael S., Robertson, Stella M., Stein, Jerry M., Evans, David G., Rauchman, Steven H., Sall, Kenneth N., Venkataraman, Subha, Chen, Bee-Lian, Wuttke, Mark, Burns, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602643/
https://www.ncbi.nlm.nih.gov/pubmed/33514891
http://dx.doi.org/10.1038/s41433-020-01391-z
_version_ 1784601614404812800
author Korenfeld, Michael S.
Robertson, Stella M.
Stein, Jerry M.
Evans, David G.
Rauchman, Steven H.
Sall, Kenneth N.
Venkataraman, Subha
Chen, Bee-Lian
Wuttke, Mark
Burns, William
author_facet Korenfeld, Michael S.
Robertson, Stella M.
Stein, Jerry M.
Evans, David G.
Rauchman, Steven H.
Sall, Kenneth N.
Venkataraman, Subha
Chen, Bee-Lian
Wuttke, Mark
Burns, William
author_sort Korenfeld, Michael S.
collection PubMed
description OBJECTIVES: This study evaluated the safety of topical lipoic acid choline ester (UNR844, 1.5%) ophthalmic solution and its efficacy in improving distance-corrected near visual acuity (DCNVA) in subjects with presbyopia. SUBJECTS AND METHODS: This was a prospective, randomized, double-masked, and multicentre clinical trial. Subjects with a diagnosis of presbyopia (n = 75) were randomized 2:1 to UNR844 or placebo. On days 1–7, all subjects were dosed unilaterally (twice a day, b.i.d.) in their non-dominant eye to ensure safety and tolerability prior to days 8–91 when dosing was changed to bilateral (b.i.d.). Clinical assessments, including DCNVA and adverse events (AEs), were recorded at each study visit. Patients who completed the study were recruited into a non-interventional follow-up study that monitored them until 7 months after their final UNR844 exposure. The primary endpoints were safety and the mean change in DCNVA from baseline in the study eye. RESULTS: UNR844 administration (n = 50) produced no safety concerns and was well-tolerated, with no clinically-relevant changes in best-corrected distance visual acuity, pupil size, intraocular pressure, or discontinuations due to adverse events. DCNVA improved in the study eye in the UNR844 group compared to placebo during the 91 days of treatment [UNR844 vs. placebo, mean change in LogMAR (SD); −0.159 (0.120) vs. −0.079 (0.116)]. Bilateral DCNVA improved, with 53.1% UNR844 vs. 21.7% placebo subjects gaining ≥10 letters. Improvements in DCNVA were sustained at 5 and 7 months after UNR844 dosing ceased. CONCLUSIONS: These results support further development of UNR844 ophthalmic solution for the treatment of presbyopia.
format Online
Article
Text
id pubmed-8602643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86026432021-12-03 Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial Korenfeld, Michael S. Robertson, Stella M. Stein, Jerry M. Evans, David G. Rauchman, Steven H. Sall, Kenneth N. Venkataraman, Subha Chen, Bee-Lian Wuttke, Mark Burns, William Eye (Lond) Article OBJECTIVES: This study evaluated the safety of topical lipoic acid choline ester (UNR844, 1.5%) ophthalmic solution and its efficacy in improving distance-corrected near visual acuity (DCNVA) in subjects with presbyopia. SUBJECTS AND METHODS: This was a prospective, randomized, double-masked, and multicentre clinical trial. Subjects with a diagnosis of presbyopia (n = 75) were randomized 2:1 to UNR844 or placebo. On days 1–7, all subjects were dosed unilaterally (twice a day, b.i.d.) in their non-dominant eye to ensure safety and tolerability prior to days 8–91 when dosing was changed to bilateral (b.i.d.). Clinical assessments, including DCNVA and adverse events (AEs), were recorded at each study visit. Patients who completed the study were recruited into a non-interventional follow-up study that monitored them until 7 months after their final UNR844 exposure. The primary endpoints were safety and the mean change in DCNVA from baseline in the study eye. RESULTS: UNR844 administration (n = 50) produced no safety concerns and was well-tolerated, with no clinically-relevant changes in best-corrected distance visual acuity, pupil size, intraocular pressure, or discontinuations due to adverse events. DCNVA improved in the study eye in the UNR844 group compared to placebo during the 91 days of treatment [UNR844 vs. placebo, mean change in LogMAR (SD); −0.159 (0.120) vs. −0.079 (0.116)]. Bilateral DCNVA improved, with 53.1% UNR844 vs. 21.7% placebo subjects gaining ≥10 letters. Improvements in DCNVA were sustained at 5 and 7 months after UNR844 dosing ceased. CONCLUSIONS: These results support further development of UNR844 ophthalmic solution for the treatment of presbyopia. Nature Publishing Group UK 2021-01-29 2021-12 /pmc/articles/PMC8602643/ /pubmed/33514891 http://dx.doi.org/10.1038/s41433-020-01391-z Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Korenfeld, Michael S.
Robertson, Stella M.
Stein, Jerry M.
Evans, David G.
Rauchman, Steven H.
Sall, Kenneth N.
Venkataraman, Subha
Chen, Bee-Lian
Wuttke, Mark
Burns, William
Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title_full Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title_fullStr Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title_full_unstemmed Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title_short Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
title_sort topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602643/
https://www.ncbi.nlm.nih.gov/pubmed/33514891
http://dx.doi.org/10.1038/s41433-020-01391-z
work_keys_str_mv AT korenfeldmichaels topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT robertsonstellam topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT steinjerrym topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT evansdavidg topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT rauchmanstevenh topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT sallkennethn topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT venkataramansubha topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT chenbeelian topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT wuttkemark topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial
AT burnswilliam topicallipoicacidcholineestereyedropforimprovementofnearvisualacuityinsubjectswithpresbyopiaasafetyandpreliminaryefficacytrial